The abstract is read at the publisher; the summary is JClub's.
In a China tertiary-center cohort of anti-MDA5 dermatomyositis, low disease activity reached 66.8% by 10 years, while drug-free remission rose to 31.0%.
- Why it matters: Anti-MDA5 dermatomyositis has high early mortality, but long-term attainment and staying power of low activity and remission are not well defined beyond the initial risk period.
- What they did: This retrospective cohort of 523 consecutive patients (median follow-up 5.7 years) tracked cumulative incidence and durability of low disease activity and drug-free remission, plus relapse and patient-reported outcomes.
- The result: Respiratory failure was linked to lower LDA and DFR rates, whereas higher CD8-positive T-cell counts were linked to higher LDA and DFR rates; 5-year relapse-free probabilities were 76.7% after LDA and 82.0% after DFR.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.